Bedrijfsoverzicht
Nutriband Inc. is a biotechnology enterprise focused on developing a portfolio of transdermal pharmaceutical products within the United States market. The company's primary strategic focus lies in creating an extended-release transdermal fentanyl product, specifically the lead candidate AVERSA fentanyl, which functions as an abuse deterrent system designed to address the opioid crisis. Operating within the Healthcare sector and the Biotechnology industry, the firm leverages specialized research capabilities to formulate these delivery systems for clinicians and patients. The company currently maintains a market capitalization of $47.48M and reports annual revenue of $2.28M, while the specific employee count is not disclosed in available filings. These valuation and revenue figures indicate that Nutriband operates as a mid-cap, pre-commercialization stage biopharmaceutical entity where the primary asset value is derived from the intellectual property and development pipeline rather than established cash-flowing operations. The significant disparity between the market cap and current revenue highlights the speculative nature of the investment, reflecting market pricing based on potential future product approvals rather than current profitability.
Financiële gezondheid
The financial statements for the trailing twelve months show a revenue of $2.28M, a net income of $-34,592,176, and an EBITDA of $-9,029,840. The substantial gap between the modest revenue of $2.28M and the massive net loss reveals a highly aggressive cost structure typical of clinical-stage biotechnology firms, where expenses related to research, development, and regulatory compliance far exceed current sales. Free cash flow stands at $-2,588,350, which indicates that the company is burning cash to fund its operations and product development, necessitating a reliance on external capital sources or existing reserves for survival. Profitability metrics are severely constrained, with a gross margin of 33.5%, an operating margin of -1121.3%, and a profit margin of 0.0%, signaling that operational costs and overheads are disproportionately high relative to current sales volume. The balance sheet shows $5.31M in cash against $258,025 in debt, resulting in a debt-to-equity ratio of 3.42, which suggests a leveraged position despite the low absolute debt amount. Although the leverage ratio appears high numerically, the absolute debt burden is minimal compared to cash holdings. The current ratio is reported at 7.53, indicating that the company possesses substantial liquid assets relative to its short-term liabilities, providing a strong buffer against immediate liquidity crises. Return on Equity is -136.1% and Return on Assets is -55.2%, metrics that mathematically reflect the heavy investment in development without yet generating returns on that capital. These negative return metrics reveal that management is currently deploying equity to fund growth initiatives rather than returning value to shareholders through earnings.
Waarderingsbeoordeling
Valuation multiples for Nutriband Inc. are atypical for profitable firms, featuring a P/E Ratio (TTM) of N/A and a forward P/E of -16.96 due to the lack of positive earnings. The negative forward P/E implies that analysts or the market expects earnings to remain negative or improve slowly, as the current trajectory does not support a traditional earnings-based multiple. The price-to-book ratio is 6.28, indicating that the stock trades at a significant premium over its book value, a common phenomenon in biotech where the intangible value of the drug pipeline exceeds the tangible assets on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 20.84 and an EV/EBITDA of -4.69 further underscore the high-risk, high-reward valuation framework applied to the company. The 52-week high was $11.68 and the 52-week low was $3.42, establishing a wide trading range that reflects high volatility in the biotechnology sector. The stock's price movement is highly sensitive to clinical trial outcomes and regulatory milestones, as evidenced by the wide spread between the high and low. The beta value of 1.93 indicates that the stock's price volatility is nearly double that of the broader market, making it a high-risk component of a diversified portfolio. This high beta confirms that the company's share price will experience amplified swings during periods of market stress or sector-specific news.
Growth & Income
Growth metrics show a revenue growth of -46.4% year-over-year, while earnings growth is N/A due to the company's current unprofitability. The negative revenue growth suggests a contraction in current sales or a reduction in the commercial footprint of existing products, which is a challenging environment for a development-stage company. Since there are no positive earnings to compare against revenue, the relationship between earnings and revenue growth is not applicable in the traditional sense, but the decline in sales indicates a lack of commercial traction at this stage. As a non-dividend payer, the company pays no dividend yield and maintains a payout ratio of 0.0%, meaning all available cash flow is retained for reinvestment into the AVERSA fentanyl program and other development activities. This strategy prioritizes funding the expensive regulatory and clinical pathways required to bring new transdermal systems to market rather than providing income to shareholders. The overall growth and income profile is characterized by significant cash burn, negative revenue momentum, and zero shareholder returns, reflecting the high-risk nature of investing in a pre-revenue biotechnology asset.